BR0112287A - Composto dds e seu método de preparação - Google Patents

Composto dds e seu método de preparação

Info

Publication number
BR0112287A
BR0112287A BR0112287-8A BR0112287A BR0112287A BR 0112287 A BR0112287 A BR 0112287A BR 0112287 A BR0112287 A BR 0112287A BR 0112287 A BR0112287 A BR 0112287A
Authority
BR
Brazil
Prior art keywords
compound
polyalcohol
dextran
aqueous solution
solution containing
Prior art date
Application number
BR0112287-8A
Other languages
English (en)
Inventor
Akihiro Imura
Takefumi Kawabe
Shigeru Noguchi
Tatsuya Yamaguchi
Tsutomu Yagi
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of BR0112287A publication Critical patent/BR0112287A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

"COMPOSTO DDS E SEU MéTODO DE PREPARAçãO". Um composto DDS em que o grupo amino na posição 1 de (1S,9S) -1-amino-9-etil-5-fluoro-2,3-diidro-9-hidroxi-4-metil-1H,12H-benzo [de] pirano [3', 4':6,7] indolizino [1,2-b] quinolina-10, 13 (9H, 15H) -diona, como um composto medicamentoso, liga-se a um grupo carboxil de um poliálcool carboximetildextrano com um espaçador contendo um aminoácido e dois a oito aminoácidos ligados por ligação(ões) de peptídeos; caracterizado pelos fatos de que uma quantidade introduzida de resíduo do composto medicamentoso está numa faixa de peso de 3,2% a 8,4%; uma média do peso molecular do poliálcool carboximetildextrano está numa faixa de 240.000 a 480.000, e um grau de carboximetilação está numa faixa de 0,14 a 0,47; e um método para preparar o referido composto DDS, que compreende os passos de, por exemplo, acrescentar uma solução aquosa contendo periodato de sódio a uma solução aquosa contendo dextrano a uma temperatura de 40<198>C <sym> 2<198>C para oxidar o dextrano e, então, acrescentar a mistura de reação resultante a uma solução aquosa contendo boroidreto de sódio a uma temperatura máxima de 15<198>C para obter um poliálcool dextrano.
BR0112287-8A 2000-06-29 2001-06-27 Composto dds e seu método de preparação BR0112287A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000195919 2000-06-29
PCT/JP2001/005498 WO2002000734A1 (fr) 2000-06-29 2001-06-27 Compose dds et son procede de preparation

Publications (1)

Publication Number Publication Date
BR0112287A true BR0112287A (pt) 2003-05-06

Family

ID=18694503

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112287-8A BR0112287A (pt) 2000-06-29 2001-06-27 Composto dds e seu método de preparação

Country Status (12)

Country Link
US (1) US20030166513A1 (pt)
EP (1) EP1298145A4 (pt)
KR (1) KR20030031502A (pt)
CN (1) CN1449412A (pt)
AU (1) AU2001267831A1 (pt)
BR (1) BR0112287A (pt)
CA (1) CA2412582A1 (pt)
IL (1) IL153505A0 (pt)
MX (1) MXPA02012791A (pt)
NO (1) NO20026212L (pt)
WO (1) WO2002000734A1 (pt)
ZA (1) ZA200300743B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531572B1 (en) 1994-07-25 2003-03-11 Roche Diagnostics Gmbh Metal chelate-labelled peptides
PL221351B1 (pl) 2012-03-14 2016-03-31 Politechnika Warszawska Sposób otrzymywania nanocząstek polisacharydowych
NZ740948A (en) 2012-10-11 2019-11-29 Daiichi Sankyo Co Ltd Glycinamide derivatives and production methods thereof
ES2782248T3 (es) * 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
SG11201605215YA (en) 2013-12-25 2016-08-30 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
KR102275925B1 (ko) 2014-01-31 2021-07-12 다이이찌 산쿄 가부시키가이샤 항-her2 항체-약물 접합체
JP2017114763A (ja) * 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
US11185594B2 (en) 2014-04-10 2021-11-30 Daiichi Sankyo Company, Limited (Anti-HER2 antibody)-drug conjugate
CN111228511B (zh) 2014-04-10 2024-06-18 第一三共株式会社 抗her3抗体-药物偶联物
CN116059395A (zh) 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
FR3045608A1 (fr) * 2015-12-18 2017-06-23 Rhodia Operations Dextrane carboxyle
TW201828993A (zh) 2016-12-12 2018-08-16 日商第一三共股份有限公司 抗體－藥物結合物與免疫檢查點抑制劑之組合
BR112019012847A2 (pt) 2017-01-17 2019-12-10 Daiichi Sankyo Co Ltd anticorpo ou fragmento funcional do anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produção de um anticorpo de interesse ou de um fragmento funcional do anticorpo e para produção de um conjugado de anticorpo-fármaco, conjugado de anticorpo-fármaco, composição farmacêutica, fármaco antitumoral, e, método de tratamento de um tumor.
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法
KR102422860B1 (ko) 2017-08-31 2022-07-19 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 신규 제조 방법
JP7366745B2 (ja) 2017-08-31 2023-10-23 第一三共株式会社 抗体－薬物コンジュゲートの改良製造方法
TWI825098B (zh) 2018-05-18 2023-12-11 德商葛萊高托普公司 抗ｍｕｃ１抗體

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69425464T2 (de) * 1993-02-26 2001-05-23 Drug Delivery System Institute, Ltd. Polysaccharidderivat und wirkstoffträger
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
TW409058B (en) * 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
KR100581443B1 (ko) * 1998-05-22 2006-05-23 다이이찌 세이야꾸 가부시기가이샤 약물복합체
EA003790B1 (ru) * 1998-10-30 2003-10-30 Дайити Фармасьютикал Ко., Лтд. Соединение сдлс и способ его измерения
EP1308171A1 (en) * 2000-07-13 2003-05-07 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing dds compounds

Also Published As

Publication number Publication date
ZA200300743B (en) 2004-02-10
NO20026212D0 (no) 2002-12-23
CA2412582A1 (en) 2002-01-03
US20030166513A1 (en) 2003-09-04
CN1449412A (zh) 2003-10-15
KR20030031502A (ko) 2003-04-21
NO20026212L (no) 2003-02-06
AU2001267831A1 (en) 2002-01-08
WO2002000734A1 (fr) 2002-01-03
IL153505A0 (en) 2003-07-06
EP1298145A1 (en) 2003-04-02
EP1298145A4 (en) 2004-12-08
MXPA02012791A (es) 2003-12-11

Similar Documents

Publication Publication Date Title
BR0112287A (pt) Composto dds e seu método de preparação
AR110986A2 (es) Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso
AP957A (en) Novel stable liquid paracetamol compositions, and method for preparing same.
EA201200490A1 (ru) Стабильный совместный состав, содержащий хиалуронидазу и иммуноглобулин, и способы его применения
FR2903107B1 (fr) Derives d&#39;imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique
ES2647843T3 (es) Formulación inyectable de ibuprofeno
BRPI0513287A (pt) derivados de pirido-pirimidina, sua preparação, sua aplicação em terapêutica
CN104491924A (zh) 可注射性载药透钙磷石骨水泥的制备方法
Sun et al. Azide‐masked resiquimod activated by hypoxia for selective tumor therapy
JP4929436B2 (ja) セファロタキシンアルカロイド組成物およびその使用
UA122762C2 (uk) Пероральна композиція 9-[(2,2-диметилпропіламіно)-метил]-міноцикліну або його солі, тверда пресована дозована форма, композиція для ін&#39;єкцій, застосування та спосіб приготування фармацевтичної композиції
KR880013572A (ko) 인슐린 및 인슐린 유도체의 혼합결정체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도
CA2404278C (en) Naphthalimide compositions and uses thereof
RU2009102803A (ru) Пригодный для инъекции состав антибиотика и раствор для его внутреннего введения
CN101416968A (zh) 一种头孢噻呋长效注射液的制备方法
UA93365C2 (ru) Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты)
PT1305057E (pt) Composicao de biomateria microparticular para uso medicinal
EA200600377A1 (ru) Новая композиция
CN105435221B (zh) 一种针对血管内皮生长因子的人源化抗体的药物组合物
CN107802602B (zh) 醋酸棉酚海藻酸钙凝胶微球的制备方法
RU2443432C2 (ru) Фармацевтическая композиция для введения инъекцией
AU777684B2 (en) Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
JP5515610B2 (ja) ソファルコン含有水性液剤
CN100379457C (zh) 阿昔洛韦注射液中阿昔洛韦的增溶方法
IE50512B1 (en) Pharmaceutical injectable composition and two-pack container for said composition

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/61 (2017.01), A61K 47/65 (2017.01), A61P 3